BACKGROUND: We evaluated the incidence and effect of thromboembolic events (TEEs) in patients with muscle-invasive bladder cancer treated with preoperative chemotherapy (POC) and radical cystectomy (RC) with pelvic lymph node dissection (PLND). PATIENTS AND METHODS: We performed a retrospective review of all patients who had undergone POC followed by RC plus PLND for muscle-invasive bladder cancer from June 2000 to January 2013 (n = 357). The chemotherapy type (neoadjuvant vs. induction), incidence and timing of TEE diagnosis (preoperatively vs. ≤ 90 days postoperatively), and effect of TEEs on clinical outcomes were recorded. RESULTS: Overall, 79 patients (22%; 95% confidence interval [CI], 18%-27%) experienced a TEE: 57 (16%) occurred during POC and 22 (6.2%) were diagnosed postoperatively. Forty patients (11%; 95% CI, 8.1%-15%) required an inferior vena cava filter. We found no significant differences in neoadjuvant versus induction chemotherapy and the risk of TEEs (difference, 3.3%; 95% CI, -5% to 12%; P = .5). No significant difference were found in the rates of POC completion according to the presence of a TEE (difference, 1.0%; 95% CI, -11% to 13%; P = .9). The occurrence of TEE did not significantly affect other perioperative outcomes. The risk of recurrence and overall survival were not associated with TEE on multivariable analysis. CONCLUSION: We found a high incidence of TEEs (22%) in patients undergoing POC before RC plus PLND, with a 16% incidence in the preoperative period. TEEs in the POC setting leads to invasive procedures; however, we did not find a significant effect on POC completion or postoperative complication risk. Further research is required to determine whether preventative TEE measures during POC can improve clinical outcomes.
BACKGROUND: We evaluated the incidence and effect of thromboembolic events (TEEs) in patients with muscle-invasive bladder cancer treated with preoperative chemotherapy (POC) and radical cystectomy (RC) with pelvic lymph node dissection (PLND). PATIENTS AND METHODS: We performed a retrospective review of all patients who had undergone POC followed by RC plus PLND for muscle-invasive bladder cancer from June 2000 to January 2013 (n = 357). The chemotherapy type (neoadjuvant vs. induction), incidence and timing of TEE diagnosis (preoperatively vs. ≤ 90 days postoperatively), and effect of TEEs on clinical outcomes were recorded. RESULTS: Overall, 79 patients (22%; 95% confidence interval [CI], 18%-27%) experienced a TEE: 57 (16%) occurred during POC and 22 (6.2%) were diagnosed postoperatively. Forty patients (11%; 95% CI, 8.1%-15%) required an inferior vena cava filter. We found no significant differences in neoadjuvant versus induction chemotherapy and the risk of TEEs (difference, 3.3%; 95% CI, -5% to 12%; P = .5). No significant difference were found in the rates of POC completion according to the presence of a TEE (difference, 1.0%; 95% CI, -11% to 13%; P = .9). The occurrence of TEE did not significantly affect other perioperative outcomes. The risk of recurrence and overall survival were not associated with TEE on multivariable analysis. CONCLUSION: We found a high incidence of TEEs (22%) in patients undergoing POC before RC plus PLND, with a 16% incidence in the preoperative period. TEEs in the POC setting leads to invasive procedures; however, we did not find a significant effect on POC completion or postoperative complication risk. Further research is required to determine whether preventative TEE measures during POC can improve clinical outcomes.
Authors: Piotr Zareba; Laurel Patterson; Rishikesh Pandya; David Margel; Sebastien J Hotte; Som D Mukherjee; Leelamma Elavathil; Dean Daya; Bobby Shayegan; Jehonathan H Pinthus Journal: Urol Oncol Date: 2014-07-11 Impact factor: 3.498
Authors: Rasanamar Sandhu; Chong-Xian Pan; Ted Wun; Danielle Harvey; Hong Zhou; Richard H White; Helen K Chew Journal: Cancer Date: 2010-06-01 Impact factor: 6.860
Authors: Vincent Q Trinh; Pierre I Karakiewicz; Jesse Sammon; Maxine Sun; Shyam Sukumar; Mai-Kim Gervais; Shahrokh F Shariat; Zhe Tian; Simon P Kim; Keith J Kowalczyk; Jim C Hu; Mani Menon; Quoc-Dien Trinh Journal: JAMA Surg Date: 2014-01 Impact factor: 14.766
Authors: Gary H Lyman; Alok A Khorana; Nicole M Kuderer; Agnes Y Lee; Juan Ignacio Arcelus; Edward P Balaban; Jeffrey M Clarke; Christopher R Flowers; Charles W Francis; Leigh E Gates; Ajay K Kakkar; Nigel S Key; Mark N Levine; Howard A Liebman; Margaret A Tempero; Sandra L Wong; Ann Alexis Prestrud; Anna Falanga Journal: J Clin Oncol Date: 2013-05-13 Impact factor: 44.544
Authors: Wilhelmina C M Duivenvoorden; Siamak Daneshmand; Daniel Canter; Yair Lotan; Peter C Black; Hamidreza Abdi; Bas W G van Rhijn; Elisabeth E Fransen van de Putte; Piotr Zareba; Ilmari Koskinen; Wassim Kassouf; Samer L Traboulsi; Janet E Kukreja; Peter J Boström; Bobby Shayegan; Jehonathan H Pinthus Journal: J Urol Date: 2016-06-14 Impact factor: 7.450
Authors: Tarik Benidir; Jaime Herrera-Caceres; Christopher Wallis; Katherine Lajkosz; Neil Fleshner Journal: Cancer Med Date: 2021-03-12 Impact factor: 4.452